Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

61. Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations

Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations Article Text Therapeutics Budesonide-formoterol for maintenance and as needed reliever treatment reduced asthma exacerbations Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2008

62. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children.

Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. BACKGROUND: Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma. Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays. OBJECTIVES: To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma. SEARCH STRATEGY: We searched the Cochrane Airways (...) Group trial register (January 2007) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997 to 2006). SELECTION CRITERIA: Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed articles for inclusion and methodological quality. One

Cochrane2007

63. Budesonide (Budenofalk) - Ulcerative colitis

Budesonide (Budenofalk) - Ulcerative colitis Scottish Medicines Consortium budesonide 2mg rectal foam (Budenofalk®) Dr Falk Pharma UK Ltd (No: 409/07) Product Update 7 September 2007 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission budesonide rectal foam (Budenofalk®) is accepted (...) for use within NHS Scotland for the treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon. It should be used in patients for whom rectally administered budesonide is an appropriate choice of treatment. It costs less than equivalent doses of the other rectal formulation of budesonide. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium

Scottish Medicines Consortium2007

65. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy Price D, Wiren A, Kuna P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three treatments for patients with persistent asthma: budesonide-formoterol Symbiotic Maintenance and Reliever Therapy (SMART) (160/4.5 μg twice daily plus additional doses as required, one inhalation twice daily); budesonide-formoterol (BUD-FORM) (320/9 μg twice daily plus as-needed terbutaline, one inhalation twice daily); and salmeterol-fluticasone (SAL-FLU) (50/250 μg twice

NHS Economic Evaluation Database.2007

68. Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma

Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Article Text Therapeutics Maintenance plus as needed budesonide plus formoterol was better than fixed dose for severe exacerbations in asthma Free P John Rees

Evidence-Based Medicine (Requires free registration)2006

69. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations

Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Article Text Treatment Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations Free Susan A Bruce , RN, MS, NP

Evidence-Based Nursing (Requires free registration)2006

70. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Dyer M J, Halpin D M, Stein K CRD summary This review evaluated (...) ciclesonide and alternative inhaled corticosteroids for asthma in adults. It concluded that there is limited evidence that inhaled ciclesonide has similar effectiveness and efficacy to fluticasone and budesonide, but no clear evidence on side-effects. The conclusions about limited evidence seem reliable; further data may become available when identified studies reported as abstracts are published in full. Authors' objectives To review published randomised controlled trials (RCTs) of the effectiveness

DARE.2006

71. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study

Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol (...) three strategies for the treatment of asthma: budesonide/formoterol 160/4.5 microgram once daily plus additional doses as needed (1xSMART); budesonide/formoterol 160/4.5 microgram twice daily plus additional doses as needed (2xSMART); budesonide/formoterol two doses of 160/4.5 microgram twice daily plus formoterol 4.5 microgram as needed (2x2FIX+F). Children aged 6 to 11 years old used the 80/4.5 microgram formulation of budesonide/formoterol with the same number of doses in each treatment strategy

NHS Economic Evaluation Database.2006

72. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study

Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Weiss K, Buxton M, Andersson F L, Lamm C J, Liljas B, Sullivan S D Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of inhaled budesonide, 200 microg once daily via Turbuhaler, in children with asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study

NHS Economic Evaluation Database.2006

75. Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief

Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief Article Text Therapeutics Combined budesonide

Evidence-Based Medicine (Requires free registration)2006

76. Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Drug Approval Package: Symbicort (budesonide/formoterol fumarate dihydrate) NDA #021929 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Symbicort (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Company: AstraZeneca Pharmaceuticals NDA: 021929 Approval Date: 7/21/2006 (PDF) (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF

FDA - Drug Approval Package2006

77. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. 16935685 2006 08 28 2006 09 07 2015 11 19 1474-547X 368 9537 2006 Aug 26 Lancet (London, England) Lancet Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. 744-53 The contributions of as-needed inhaled corticosteroids and long-acting beta2 agonists (LABA (...) ) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting beta2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide-formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy. We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled

Lancet2006

78. Budesonide for induction of remission in Crohn's disease.

Budesonide for induction of remission in Crohn's disease. BACKGROUND: Corticosteroids continue to play a central role in induction of remission in active Crohn's disease. However, their use comes at a price of significant adverse effects when used repeatedly or for extended periods. Newer corticosteroid agents with limited systemic bioavailability offer a tantalizing option, if they can be shown to be efficacious and safer than conventional corticosteroids. Budesonide is the main alternative (...) corticosteroid currently available in an enteric formulation. OBJECTIVES: To evaluate the effectiveness of oral budesonide for the treatment of acute flares of Crohn's disease. A secondary but important endpoint was to evaluate the adverse effect profile. SEARCH STRATEGY: The following sources were used to search the literature for potentially relevant papers and trials. 1. A computer-assisted search of the on-line bibliographic database MEDLINE from 1986 onwards. 2. Hand searching the reference lists

Cochrane2005

79. Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day

Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day Article Text Economics Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day Free Jay Peters

Evidence-Based Medicine (Requires free registration)2005

80. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, Meyer-Sabellek W, Buhl (...) R, Willich S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two strategies for the treatment of asthma were examined, adjustable maintenance versus fixed treatment. Both strategies were based on a combination of budesonide

NHS Economic Evaluation Database.2005